To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients
The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed
Prostate Cancer
DRUG: LHRH analogues
Percentage of patients for whom the initial LHRH prescription (the prescription at the baseline visit) has been renewed at first follow-up visit (same type, same formulation)., First follow-up visit (occurs 3 to 6 months from baseline)
Percentage of patients for whom the initial LHRH prescription has been renewed at each visit., Baseline, between 3 to 6 months, 12 months, 18 months and 24 months|Percentage of patients having switched from a 3 months to a 6 months and also 6 months to 3 months formulation at each visit., Baseline, between 3 to 6 months, 12 months, 18 months and 24 months|Percentage of patients starting a 6-month formulation at baseline., The decision to prescribe a LHRH analogue as a 3- or 6-months formulation will be made prior to and independently from the decision to enroll the subject. This decision should be made in accordance with the usual medical practice of the concerned investigator., Baseline|Reasons leading to a switch from a 3 months to a 6 months formulation (patient) presented as proportion of patients, Baseline, between 3 to 6 months, 12 months, 18 months and 24 months|Reasons leading to a switch from a 3 months to a 6 months formulation (physician) presented as proportion of physicians, Baseline, between 3 to 6 months, 12 months, 18 months and 24 months|Criteria for choice of formulation at start of hormonal treatment taking into consideration the patient characteristics and his disease status., Baseline|Change of the Quality of Life Questionnaire QLQ-PR25 score compared to baseline and each visit., Baseline, between 3 to 6 months, 12 months, 18 months and 24 months|Correlation between physician and patient satisfaction and the evolution of the biological parameters (Prostate-specific antigen), Baseline, between 3 to 6 months, 12 months, 18 months and 24 months|Percentage of patients for which the initial prescription (the prescription at the baseline visit) of a LHRH analogue (3 or 6 months) has been stopped and later on renewed (intermittent treatment), Baseline, between 3 to 6 months, 12 months, 18 months and 24 months
The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed